|
Active substance |
dostarlimab |
|
Holder |
GlaxoSmithKline Pharmaceuticals |
|
Status |
closed |
|
Indication |
as monotherapy for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) recurrent or advanced endometrial cancer (EC) that has progressed on or following prior treatment with a platinum-containing regimen. |
|
Public documents |
|
|
Last update |
02/12/2022 |
Jemperli®
Last updated on 10/09/2024